Cl[C:2]1[CH:9]=[CH:8][C:5]([C:6]#[N:7])=[C:4]([N+:10]([O-:12])=[O:11])[CH:3]=1.C[O-].[Na+].C(N(CC)CC)C.[CH3:23][C@H:24]1[CH2:29][NH:28][CH2:27][C@@H:26]([CH3:30])[NH:25]1>CC(O)=O.CC(P(C(C)(C)C)C1C(C2[C-]=CC=CC=2)=CC=CC=1)(C)C.[Pd]>[CH3:23][C@H:24]1[NH:25][C@@H:26]([CH3:30])[CH2:27][N:28]([C:2]2[CH:9]=[CH:8][C:5]([C:6]#[N:7])=[C:4]([N+:10]([O-:12])=[O:11])[CH:3]=2)[CH2:29]1A mixture of 4-chloro-2-nitrobenzonitrile (Tetrahedron 1994, 50, 5515-5126) (650 mg, 3.56 mmol), sodium methoxide (270 mg, 5.00 mmol) and acetato-(2′-di-tert-butylphosphino-1,1′-biphenyl-2-yl)palladium (II) (115 mg, 0.25 mmol) was treated with triethylamine (0.25 ml, 1.79 mmol) followed by cis-2,6-dimethylpiperazine (488 mg, 4.27 mmol) and the mixture heated to 85° C. under an inert atmosphere over 30 minutes. The mixture was then kept at this temperature for 16 hours. The mixture was then filtered through kieselguhr, washing with toluene (50 ml) and the filtrate reduced in vacuo. The residue was then purified using an SCX ion exchange cartridge (Varian bond-elute) eluting with methanol followed by 2M ammonia in methanol to afford a dark residue which was purified by mass directed autoprep BPLC to afford the title compound as the formic acid salt. MS (ES+) m/e 261 [M+H]+.
読み込み中…
